(S021) Success of Prophylactic Single-Fraction Radiation Therapy in the Prevention of Pathologic Femoral Fractures

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

Single-fraction RT to the femur was effective in the prevention of femoral fractures. The pain score was also decreased in our patient population. Further studies are needed to explore 8 Gy/1 fx against standard radiation as a more effective means of delivering therapeutic and convenient treatment in metastatic patients.

Tijana Skrepnik, MD, Lauren Eisenberg, BS, Hitendra Patel, MD, Krisha Howell, MD; Department of Radiation Oncology, Department of Hematology/Oncology, Banner/University of Arizona Hospitals; University of Arizona

INTRODUCTION: Femoral metastases pose a threat of fracture. A low Mirel bone score (MBS) of < 8 points predicts a fracture rate of ~4% with standard fractionation radiation therapy (RT) alone. A score of > 8 points indicates a risk of fracture of 15% or higher, suggesting a role for surgical stabilization in addition to standard RT. Little data exist confirming the efficacy of single-fraction RT for fracture prevention.

METHODS: We performed a retrospective review of femoral metastases treated to 8 Gy × one fraction (fx). Relevant images and pain scores were reviewed for bony stability and assigned an MBS. Surgical consultation/intervention, prospectively acquired pain scores/toxicity assessments, and in-field fracture rates as reported on follow-up imaging were assessed.

RESULTS: In reviewing 198 charts, 24 metastatic femoral lesions from nonmyelomatous primaries were identified. Median clinical and radiographic follow-up was 1 month and 3 months, with a median overall survival status postcompletion of therapy of 4.3 months (range: 0.3–31.9 mo). The highest fracture risk region (peritrochanteric) constituted 41.7% of lesions, followed by head/neck (33.3%), femoral shaft (20.8%), and epiphyseal (4%) locations. Median MBS was 8 (range: 6–12), and two-thirds of patients did not receive a surgical consult. There were three fractures prior to RT (one nondisplaced, one previously stabilized, and one impending). Four sites received surgical intervention with a median intervention time of 14 months before RT (range: 0.4–24 mo). All (100%) irradiated bony sites had no subsequent fractures. Median pretreatment and posttreatment pain scores were 7 and 0, respectively, with a median improvement of 6 points on the pain scale.

CONCLUSION: Single-fraction RT to the femur was effective in the prevention of femoral fractures. The pain score was also decreased in our patient population. Further studies are needed to explore 8 Gy/1 fx against standard radiation as a more effective means of delivering therapeutic and convenient treatment in metastatic patients.

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
Only a few groups of patients get screened for pancreatic cancer, those with a genetic risk or pancreatic cysts among them, which can increase lethality for unidentified populations.
The development of RAS-directed vaccines may help decrease the likelihood of disease recurrence in patients undergoing treatment for pancreatic cancer.
Medical use of AI increases every day, and in the future, will be exponentially greater and many forms of treatment will be improved, according to Russell C. Langan, MD, FACS, FSSO.
Shubham Pant, MD, MBBS, highlights an “exciting time” in the treatment of patients with RAS-mutated pancreatic cancer.
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
A computational linguistics model designed to locate pancreatic cysts that started to locate pancreatic cancer has the potential to lead to more efficient treatment.
Related Content